New Jersey is currently home to 1696 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Bright Ideas - CIN Feasibility Study
NCT04929899
Recruiting
In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
01/28/2025
Locations: Rutgers Cancer Institute, New Brunswick, New Jersey
Conditions: Acute Lymphoblastic Leukemia (ALL)
Register for Updates
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Solid Tumors
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution - 008, Does Not Exist, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Digital Incentive Spirometry Adherence
NCT06629454
Recruiting
This single-arm proof-of-concept research study aims to assess the effect of a digital incentive spirometer (IS) device and a companion mobile-based app on incentive spirometry adherence in patients post-surgery. The digital IS utilizes a sensor to measure inspiratory breaths, and these data are transmitted wirelessly to a secure cloud database. The spirometer and app include a patient reminder system, exercise gamification strategies, progress tracking, and additional features designed to promo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Penn Medicine Cherry Hill, Cherry Hill, New Jersey
Conditions: Pulmonary Function, Incentive Spirometry, Patient Adherence, Lung Resection, Thoracic Surgery
Register for Updates
Safety and Efficacy of VDPHL01 in Males and Females with AGA
NCT06527365
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and inc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/27/2025
Locations: 03, Hackensack, New Jersey
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Rutgers University, New Brunswick, New Jersey
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
NCT05818553
Recruiting
This is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
01/24/2025
Locations: Praxis Research Site, Hackensack, New Jersey
Conditions: SCN2A Encephalopathy, SCN8A Encephalopathy
Register for Updates
Basic and Applied Research on Extinction Bursts
NCT05925101
Recruiting
Although highly effective, treatments like FCT include extinction, which can have adverse side effects. The extinction burst, an increase in the frequency or intensity of destructive behavior at the start of treatment, is the most common side effect of extinction, and can increase the risk of harm to the patient and others. The goal of the current study is to evaluate the prevalence of extinction bursts when various parameters of reinforcement (i.e., rate, magnitude, quality) are manipulated.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
01/23/2025
Locations: Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and Services, Somerset, New Jersey
Conditions: Problem Behavior, Aggression, Self Injury
Register for Updates
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
NCT05383274
Recruiting
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Gender:
MALE
Ages:
Between 22 years and 65 years
Trial Updated:
01/23/2025
Locations: New Jersey Urolgy, Millburn, New Jersey
Conditions: Urethral Stricture
Register for Updates
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Arthritis & Osteoporosis Associates, PA, Freehold, New Jersey
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates